Revenue during the quarter grew 15.95 percent to $4.91 million from $4.24 million in the previous year period. Gross margin for the quarter expanded 685 basis points over the previous year period to 47.74 percent. Total expenses were 84.66 percent of quarterly revenues, down from 88.23 percent for the same period last year. This has led to an improvement of 357 basis points in operating margin to 15.34 percent.

Operating income for the quarter was $0.75 million, compared with $0.50 million in the previous year period.

However, the adjusted EBITDA for the quarter stood at $2.62 million compared with $2.13 million in the prior year period. At the same time, adjusted EBITDA margin improved 300 basis points in the quarter to 53.24 percent from 50.24 percent in the last year period.

Chairman and chief executive officer Ernest A. Bates, M.D. said, "Patient treatments that began in April 2016 at our proton center at UF Health Cancer Center-Orlando Health continue to drive improved financial performance for AMS. Treatment volume at this center increased to 1,220 fractions in the first quarter, compared to 1,019 fractions performed in last year's fourth quarter, 869 fractions performed in the third quarter and 442 fractions performed in the second quarter. The reliability and throughput of the MEVION S250 proton system we supplied Orlando Health is meeting or exceeding our expectations, and we believe there is room for further growth in treatment volume.